Horizon Discovery Group PLC (LON:HZD)‘s stock had its “buy” rating reiterated by Numis Securities Ltd in a research note issued to investors on Tuesday. They presently have a GBX 260 ($3.39) price target on the stock. Numis Securities Ltd’s price target would indicate a potential upside of 57.58% from the stock’s previous close.

A number of other research firms have also weighed in on HZD. Panmure Gordon reaffirmed a “buy” rating and set a GBX 270 ($3.52) target price on shares of Horizon Discovery Group PLC in a report on Wednesday, June 1st. Beaufort Securities reissued a “speculative buy” rating on shares of Horizon Discovery Group PLC in a report on Friday, September 2nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Horizon Discovery Group PLC has a consensus rating of “Buy” and an average price target of GBX 217.25 ($2.84).

Analyst Recommendations for Horizon Discovery Group PLC (LON:HZD)

Horizon Discovery Group PLC (LON:HZD) opened at 153.40 on Tuesday. The company’s market cap is GBX 144.33 million. The company’s 50-day moving average is GBX 160.39 and its 200-day moving average is GBX 160.58. Horizon Discovery Group PLC has a 52 week low of GBX 125.00 and a 52 week high of GBX 188.06.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/horizon-discovery-group-plc-hzd-rating-reiterated-by-numis-securities-ltd.html

About Horizon Discovery Group PLC

Horizon Discovery (LSE: HZD) is a world-leading gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. Horizon’s proprietary gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.

Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.